HESTA has pledged to support equitable access to COVID-19 vaccines globally and has committed to investment approaches that will support the push for greater vaccine access.
The industry superannuation fund said uneven vaccination rates posed a risk to global health and economic activity in 2021, leading it to sign an investor statement pushing for urgent G7 and G20 governments to take action.
HESTA chief executive, Debby Blakey, said a successful and equitable global distribution of vaccines would have an impact on the pact of economic recovery, and therefore HESTA members’ investments.
HESTA pointed to a study by the International Chamber of Commerce Research Foundation that found the global economy stood to lose as much as US$9.2 trillion ($11.6 trillion) if the COVID-19 vaccines are not widely available in developing countries.
“Ensuring developing economies have equal access to COVID-19 vaccines, medicines and tests will reduce the impact of COVID-19 worldwide, and help foster a fairer and more sustainable global recovery,” Blakey said.
“We’re keen to work with other global investors to explore ways we can encourage further investment that will help fund vaccine distribution.”
The lower outlook for inflation has set the stage for another two rate cuts over the first half of 2026, according to Westpac.
With private asset valuations emerging as a key concern for both regulators and the broader market, Apollo Global Management has called on the corporate regulator to issue clear principles on valuation practices, including guidance on the disclosures it expects from market participants.
Institutional asset owners are largely rethinking their exposure to the US, with private markets increasingly being viewed as a strategic investment allocation, new research has shown.
Australia’s corporate regulator has been told it must quickly modernise its oversight of private markets, after being caught off guard by the complexity, size, and opacity of the asset class now dominating institutional portfolios.